StockNews.AI
ANIX
StockNews.AI
176 days

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

1. Anixa’s CAR-T therapy for ovarian cancer featured in Breaking Cancer News. 2. Moffitt Cancer Center leads clinical trial targeting FSHR on cancer cells. 3. Licensed technology from The Wistar Institute underpins the novel approach. 4. Potential repeat dosing study hints at expanded treatment strategies. 5. Positive recognition may enhance ANIX’s reputation and long-term prospects.

7m saved
Insight
Article

FAQ

Why Bullish?

The breakthrough in CAR-T therapy, showcased through a robust partnership with Moffitt, is likely to drive investor confidence, similar to past positive clinical trial announcements by biotech firms that spurred bullish price movements.

How important is it?

While the announcement indicates a promising clinical advancement and strong collaboration, inherent biotech risks and the early-stage nature of the program moderate its immediate impact.

Why Long Term?

Since clinical results and regulatory milestones require time, the full benefits of this innovation are expected to materialize over the long run, akin to previous transformative approvals in oncology.

Related Companies

GILD
, /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer." The article highlights the groundbreaking clinical trial led by Dr. Robert Wenham, Chairman of the Department of Gynecologic Oncology at Moffitt Cancer Center, and Dr. Monica Avila, a leading gynecologic oncologist at Moffitt. The trial explores the use of chimeric antigen receptor-T cell (CAR-T) therapy to treat ovarian cancer, a disease with historically limited treatment options for advanced-stage patients. The CAR-T therapy being studied in this trial, exclusively licensed to Anixa from The Wistar Institute, and developed through a partnership between Anixa and Moffitt, is designed to target the follicle-stimulating hormone receptor (FSHR), a protein uniquely expressed on ovarian cancer cells. This novel approach has the potential to revolutionize the treatment of ovarian cancer by leveraging the body's immune system to directly attack tumors. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "We are honored to see our work recognized in Breaking Cancer News and to witness the promising impact this CAR-T therapy is having on patients. Our partnership with Moffitt Cancer Center exemplifies our commitment to developing novel and targeted immunotherapies that could transform the standard of care for some of the most challenging cancers, including ovarian cancer." The article also highlights the potential expansion of the study to evaluate repeat dosing, given Gallagher's response, and explores the broader implications of CAR-T therapy for solid tumors—an area of intense research and high unmet medical need. The full article can be accessed here: https://breakingcancernews.com/2025/02/18/navigating-uncharted-territory-car-t-for-ovarian-cancer/. About Anixa Biosciences, Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFO[email protected]408-708-9808 SOURCE Anixa Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News